RU2700083C2 - Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака - Google Patents
Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака Download PDFInfo
- Publication number
- RU2700083C2 RU2700083C2 RU2015128913A RU2015128913A RU2700083C2 RU 2700083 C2 RU2700083 C2 RU 2700083C2 RU 2015128913 A RU2015128913 A RU 2015128913A RU 2015128913 A RU2015128913 A RU 2015128913A RU 2700083 C2 RU2700083 C2 RU 2700083C2
- Authority
- RU
- Russia
- Prior art keywords
- cells
- deltac
- cancer
- tumor
- strain
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
- C12N2760/18462—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305086.4A EP2759301A1 (en) | 2013-01-24 | 2013-01-24 | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
| EP13305086.4 | 2013-01-24 | ||
| PCT/EP2014/051063 WO2014114605A1 (en) | 2013-01-24 | 2014-01-20 | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015128913A RU2015128913A (ru) | 2017-03-02 |
| RU2700083C2 true RU2700083C2 (ru) | 2019-09-12 |
Family
ID=47683672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128913A RU2700083C2 (ru) | 2013-01-24 | 2014-01-20 | Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9889193B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2759301A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6382223B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107223055A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015017692B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2898370C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2948157T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2700749T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2948157T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2700083C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014114605A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2759301A1 (en) * | 2013-01-24 | 2014-07-30 | Institut Pasteur | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
| CN107085095A (zh) * | 2017-03-02 | 2017-08-22 | 江苏华冠生物技术股份有限公司 | 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法 |
| US11633441B2 (en) | 2017-12-01 | 2023-04-25 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| CN117323421A (zh) * | 2022-06-24 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012022495A1 (en) * | 2010-08-20 | 2012-02-23 | Lauer Ulrich M | Oncolytic measles virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| EP1375512B1 (en) | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| CA2508266A1 (fr) | 2005-06-20 | 2006-12-20 | Institut Pasteur | Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae |
| DK1939214T3 (da) | 2006-12-22 | 2013-10-14 | Pasteur Institut | Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira |
| EP2058003A1 (en) * | 2007-10-10 | 2009-05-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Medicaments and methods for treating mesothelioma |
| US9399062B2 (en) * | 2011-01-18 | 2016-07-26 | Christopher D. Richardson | PVRL4 (Nectin4) is a receptor for measles virus |
| EP2759301A1 (en) * | 2013-01-24 | 2014-07-30 | Institut Pasteur | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
-
2013
- 2013-01-24 EP EP13305086.4A patent/EP2759301A1/en not_active Withdrawn
-
2014
- 2014-01-20 EP EP14701698.4A patent/EP2948157B1/en active Active
- 2014-01-20 JP JP2015554120A patent/JP6382223B2/ja active Active
- 2014-01-20 BR BR112015017692-5A patent/BR112015017692B1/pt not_active IP Right Cessation
- 2014-01-20 WO PCT/EP2014/051063 patent/WO2014114605A1/en not_active Ceased
- 2014-01-20 CA CA2898370A patent/CA2898370C/en active Active
- 2014-01-20 CN CN201480017539.6A patent/CN107223055A/zh active Pending
- 2014-01-20 ES ES14701698T patent/ES2700749T3/es active Active
- 2014-01-20 US US14/762,559 patent/US9889193B2/en active Active
- 2014-01-20 DK DK14701698.4T patent/DK2948157T3/en active
- 2014-01-20 PL PL14701698T patent/PL2948157T3/pl unknown
- 2014-01-20 RU RU2015128913A patent/RU2700083C2/ru active
-
2018
- 2018-01-25 US US15/880,133 patent/US10314905B2/en active Active
-
2019
- 2019-06-03 US US16/429,571 patent/US10980873B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012022495A1 (en) * | 2010-08-20 | 2012-02-23 | Lauer Ulrich M | Oncolytic measles virus |
Non-Patent Citations (7)
| Title |
|---|
| FRANK RADECKE et al., The Nonstructural C Protein Is Not Essential for Multiplication of Edmonston B Strain Measles Virus in Cultured Cells, VIROLOGY 1996, Vol.217, pp. 418-421. * |
| FRANK RADECKE et al., The Nonstructural C Protein Is Not Essential for Multiplication of Edmonston B Strain Measles Virus in Cultured Cells, VIROLOGY 1996, Vol.217, pp. 418-421. KAORU TAKEUCHI et al., Stringent Requirement for the C Protein of Wild-Type Measles Virus for Growth both In Vitro and in Macaques, JOURNAL OF VIROLOGY, June 2005, Vol. 79, No. 12, pp.7838-7844. JEAN-BAPTISTE GUILLERME et al., Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells, Clin Cancer Res January 21, 2013, Vol.19, No.5, pp.1147-1159. * |
| GUY UNGERECHTS et al., Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics, Gene Ther. 2010 December ; 17(12): 1506-1516. * |
| GUY UNGERECHTS et al., Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics, Gene Ther. 2010 December ; 17(12): 1506-1516. Ю.И. АММУР и др., ВИРУС КОРИ КАК ОНКОЛИТИЧЕСКИЙ АГЕНТ, Вопросы вирусологии, 2013, S1, стр.116-131. * |
| JEAN-BAPTISTE GUILLERME et al., Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells, Clin Cancer Res January 21, 2013, Vol.19, No.5, pp.1147-1159. * |
| KAORU TAKEUCHI et al., Stringent Requirement for the C Protein of Wild-Type Measles Virus for Growth both In Vitro and in Macaques, JOURNAL OF VIROLOGY, June 2005, Vol. 79, No. 12, pp.7838-7844. * |
| Ю.И. АММУР и др., ВИРУС КОРИ КАК ОНКОЛИТИЧЕСКИЙ АГЕНТ, Вопросы вирусологии, 2013, S1, стр.116-131. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016506722A (ja) | 2016-03-07 |
| US9889193B2 (en) | 2018-02-13 |
| US10980873B2 (en) | 2021-04-20 |
| CN107223055A (zh) | 2017-09-29 |
| BR112015017692A2 (pt) | 2019-11-19 |
| ES2700749T3 (es) | 2019-02-19 |
| WO2014114605A1 (en) | 2014-07-31 |
| JP6382223B2 (ja) | 2018-08-29 |
| RU2015128913A (ru) | 2017-03-02 |
| DK2948157T3 (en) | 2019-01-07 |
| US10314905B2 (en) | 2019-06-11 |
| US20180221469A1 (en) | 2018-08-09 |
| US20200016260A1 (en) | 2020-01-16 |
| PL2948157T3 (pl) | 2019-03-29 |
| US20150359873A1 (en) | 2015-12-17 |
| EP2948157A1 (en) | 2015-12-02 |
| EP2948157B1 (en) | 2018-10-10 |
| EP2759301A1 (en) | 2014-07-30 |
| CA2898370C (en) | 2020-01-14 |
| BR112015017692B1 (pt) | 2021-11-03 |
| CA2898370A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gauvrit et al. | Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response | |
| CA3030451C (en) | Compositions and methods for alphavirus vaccination | |
| KR20170003920A (ko) | 종양분해성 백시니아 바이러스 | |
| JP2018519847A (ja) | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 | |
| US10980873B2 (en) | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy | |
| US20230248819A1 (en) | Nucleic acid lipid particle vaccine | |
| US20200246443A1 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
| JP2017509652A (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
| JP2023523423A (ja) | SARS-CoV-2に対するワクチン及びその調製物 | |
| JP2021516957A (ja) | パラポックスウイルスベクター | |
| US9636395B2 (en) | Medicaments and methods for treating mesothelioma | |
| CN116650633A (zh) | 冠状病毒疫苗 | |
| CA2615687A1 (en) | Immune response inducing preparations | |
| HK40097472A (en) | Coronavirus vaccine | |
| KR20250089555A (ko) | 면역요법 조성물 및 사용 방법 | |
| HK40116087A (en) | Oncolytic virus simultaneously expressing cd55 and cd59 | |
| CN108239660B (zh) | 一种重组结核病疫苗,其制备方法及应用 | |
| WO2024062098A1 (en) | Recombinant pseudocowpox virus encoding an interleukin-12 |